Horizon Bancorp, Inc. Announces Completion of $100 Million Subordinated Notes Offering
HZNP(NASDAQ:HZNP) Horizon Bancorp, Inc. announces completion of $100 million subordinated notes offering.
August 29, 2025Debt Offering
Read more →Horizon Bancorp, Inc. Announces Closing of Common Stock Offering
HZNPHorizon Bancorp today announced the closing of the previously announced underwritten public offering of 7,138,050 shares of its common stock.
August 22, 2025Equity Offering
Read more →Horizon Bancorp, Inc. Announces Launch of Common Stock Offering
HZNPHorizon Bank, announced today that it has launched an underwritten public offering of shares of its common stock.
August 20, 2025Equity
Read more →Horizon Therapeutics Announces Data From The MIRROR Randomized Controlled Trial Of KRYSTEXXA Injection With Methotrexate Published In Arthritis & Rheumatology
HZNPSeptember 14, 2022
Read more →Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep For The Treatment Of Sjögren's Syndrome Meets Primary Endpoint
HZNPSeptember 12, 2022
Read more →Horizon Therapeutics plc Announces $500M Share Repurchase Program
HZNPSeptember 9, 2022
Read more →Horizon Therapeutics: Q1 Earnings Insights
HZNPHorizon Therapeutics (NASDAQ:HZNP) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
May 4, 2022
Read more →Horizon Therapeutics Q1 Adj. EPS $1.34 Beats $1.20 Estimate, Sales $885.20M Beat $874.41M Estimate; Reaffirms FY22 Guidance
HZNPMay 4, 2022
Read more →Horizon Therapeutics Announces Phase 2 Trial Of Dazodalibep Met Primary Endpoint
HZNPMay 3, 2022
Read more →Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation
HZNPMay 2, 2022
Read more →Horizon Therapeutics Received European Commission Approval of UPLIZNA for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder
HZNPMay 2, 2022
Read more →Will Investors Notice Exciting Sign On Horizon Therapeutics's Chart?
HZNPIf history is any guide, there may be good fortune ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
April 28, 2022
Read more →